Deerfield Management raised a new $600 million fund to invest in life sciences and health care companies, but it wasn't easy amid a turbulent IPO market, managing partner Jim Flynn tells Axios.
Why it matters: Fundraising began about 18 months ago, Flynn says, signaling investors' hesitancy to invest in the life sciences sector amid market challenges being worsened by uncertain tariffs and FDA activity.
